Clinical Trials Logo
  1. Home
  2. Polycystic Liver Disease
  3. NCT01315795

Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease — LOCKCYST  

Polycystic Liver Disease Clinical Trial

Official title:
An Open-label, Phase II Clinical Study to Evaluate the Efficacy and Safety of Lanreotide Autogel 90mg Every 4 Weeks in the Treatment of Symptomatic Polycystic Liver Disease, Including a Dose Escalation at Month 6 to Lanreotide Autogel 120mg for Non Responders

Clinical Trial Summary

An open-label, Phase II clinical study to evaluate the efficacy and safety of lanreotide autogel 90mg every 4 weeks in the treatment of symptomatic polycystic liver disease, including a dose escalation at month 6 to lanreotide autogel 120mg for non responders.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01315795
Study type Interventional
Source Universitaire Ziekenhuizen Leuven
Contact
Status Completed
Phase Phase 2/Phase 3
Start date March 2011
Completion date July 2014
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05215964 - The Association Between Skeletal Muscle Mass and Severity of Polycystic Liver Disease and Polycystic Kidney Disease
Completed NCT00565097 - Lanreotide as Treatment of Polycystic Livers Phase 2/Phase 3
Recruiting NCT05500157 - Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts N/A
Completed NCT01354405 - Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE) N/A
Active, not recruiting NCT05281328 - A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD Phase 2/Phase 3
Recruiting NCT02173080 - Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).
Completed NCT01157858 - Everolimus and LongActing Octreotide Trial in Polycystic Livers Phase 2
Recruiting NCT05478083 - A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease Phase 2
Recruiting NCT04645251 - Polycystic Liver Disease Registry (UK)
Completed NCT00426153 - Octreotide in Severe Polycystic Liver Disease Phase 2/Phase 3
Terminated NCT00934791 - Polycystic Liver Disease in Kidney Transplant N/A
Completed NCT02021110 - Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease Phase 2
Completed NCT01670110 - Pasireotide LAR in Severe Polycystic Liver Disease Phase 2
Active, not recruiting NCT00771888 - Open-Label Extension of LOCKCYST Trial Phase 2/Phase 3
Recruiting NCT03960710 - Automatic Segmentation of Polycystic Liver